We are dedicated to small-sized markets, which are less easy for major pharmaceutical companies to enter, such as cancer, hematology, and pain management. We will continue to increase revenue by aggressively launching innovative pharmaceuticals.
Our experts with extensive experience in drug discovery and evaluation drive our "New Drug Search Engine" to globally navigate through information about new drugs from bio-ventures, laboratories and pharmaceutical companies. They select, with their highly discerning capacity, the most promising and potentially most profitable drug candidates that are likely to meet compelling medical needs. Our Scientific Advisory Board, (SAB), comprised of highly experienced and leading professional clinicians and scientists in basic research, provides impartial screening of the drug candidates and brings them into the pipelines.
We use clinical data previously obtained in other countries to allow our clinical studies to start at later development stages in order to complete the development process in an accelerated manner and acquire marketing approval at a higher rate. In addition, collaborating with other organizations enables a labless/fabless development scheme and low-cost management. This helps us maximize the value of your investment.
We acquired the rights to develop and commercialize this agent in 2005 and brought it to market in December 2010, only five years later. More than 21,000 patients with non-Hodgkin's lymphoma have received this anti-cancer agent.
Also, in August 2016, we obtained approval for chronic lymphocytic leukemia as an additional indication.
As well as these indications, in December 2016 SymBio obtained approval for the additional indication of first-line treatment of low-grade non-Hodgkin's lymphoma and mantle cell lymphoma. Moreover, we initiated a phase 3 study for the indication of relapsed/refractory diffuse large B-cell lymphoma, or r/r DLBCL, in August 2017.
Since its incorporation, SymBio has focused on implementing a product lifecycle management strategy to maximize the business value of TREAKISYM® and as a part of this strategy, the Company has pursued the expansion of approved indications.
On September 20, 2017, SymBio obtained the exclusive rights from Eagle Pharmaceuticals, Inc. (New Jersey) for its patent-protected bendamustine liquid formulations, ready-to-dilute and rapid infusion, (RTD and RI), which enable SymBio to extend the product life of TREAKISYM® until 2031. We position RTD and RI formulations as the next generation of TREAKISYM® in the TREAKISYM® platform strategy.
We acquired the exclusive license for this agent in 2011. We started a global phase 3 trial for IV rigosertib as a treatment for relapsed/refractory higher-risk myelodysplastic syndromes (MDS) in December 2015. We also started a phase 1 clinical trial for high-dose oral rigosertib. Apart from this anti-cancer agent, there currently exists only one agent commercially available for MDS in Japan. Rigosertib has attracted strong interest from patients and the healthcare community.
We acquired the global exclusive license for this antiviral drug on September, 2019.
We plan to initiate the domestic clinical trial initially targeting treatment of viral hemorrhagic cystitis (vHC) and HHV-6 encephalitis after allogeneic hematopoietic stem cell transplantation. Although other antiviral drugs are currently used for these diseases, there is a long-standing and significant medical need for a treatment that is both effective and safe.
SymBio Pharmaceuticals will continue to build on key products and aggressively add new pipelines.
rigosertib SyB L-1101/SyB C-1101